Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Thalamic Atrophy Without Whole Brain Atrophy Is Associated With Absence of 2-Year NEDA in Multiple Sclerosis.

Hänninen K, Viitala M, Paavilainen T, Karhu JO, Rinne J, Koikkalainen J, Lötjönen J, Soilu-Hänninen M.

Front Neurol. 2019 May 3;10:459. doi: 10.3389/fneur.2019.00459. eCollection 2019.

2.

Progressive multifocal leukoencephalopathy in Finland: a cross-sectional registry study.

Sipilä JOT, Soilu-Hänninen M, Rautava P, Kytö V.

J Neurol. 2019 Feb;266(2):515-521. doi: 10.1007/s00415-018-09167-y. Epub 2019 Jan 5.

3.

Multiple sclerosis epidemiology in Finland: Regional differences and high incidence.

Pirttisalo AL, Soilu-Hänninen M, Sipilä JOT.

Acta Neurol Scand. 2019 Apr;139(4):353-359. doi: 10.1111/ane.13057. Epub 2019 Jan 3.

PMID:
30480315
4.

Multiple sclerosis registries in Europe - An updated mapping survey.

Glaser A, Stahmann A, Meissner T, Flachenecker P, Horáková D, Zaratin P, Brichetto G, Pugliatti M, Rienhoff O, Vukusic S, de Giacomoni AC, Battaglia MA, Brola W, Butzkueven H, Casey R, Drulovic J, Eichstädt K, Hellwig K, Iaffaldano P, Ioannidou E, Kuhle J, Lycke K, Magyari M, Malbaša T, Middleton R, Myhr KM, Notas K, Orologas A, Otero-Romero S, Pekmezovic T, Sastre-Garriga J, Seeldrayers P, Soilu-Hänninen M, Stawiarz L, Trojano M, Ziemssen T, Hillert J, Thalheim C.

Mult Scler Relat Disord. 2019 Jan;27:171-178. doi: 10.1016/j.msard.2018.09.032. Epub 2018 Oct 4. No abstract available.

PMID:
30384204
5.

Adult hospital admissions associated with multiple sclerosis in Finland in 2004-2014.

Pirttisalo AL, Sipilä JOT, Soilu-Hänninen M, Rautava P, Kytö V.

Ann Med. 2018 Jun;50(4):354-360. doi: 10.1080/07853890.2018.1461919. Epub 2018 Apr 17.

PMID:
29629575
6.

Author response: 25-Hydroxyvitamin D deficiency and risk of MS among women in the Finnish Maternity Cohort.

Munger KL, Ascherio A, Soilu-Hänninen M, Surcel HM, Åivo J.

Neurology. 2018 Apr 3;90(14):668-669. doi: 10.1212/WNL.0000000000005245. No abstract available.

PMID:
29610235
7.

Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab.

Saarela M, Senthil K, Jones J, Tienari PJ, Soilu-Hänninen M, Airas L, Coles A, Saarinen JT.

Neurology. 2018 May 1;90(18):849-851. doi: 10.1212/WNL.0000000000005420. Epub 2018 Mar 30. No abstract available.

PMID:
29602914
8.

Efficacy and safety outcomes in vitamin D supplement users in the fingolimod phase 3 trials.

Hongell K, Silva DG, Ritter S, Meier DP, Soilu-Hänninen M.

J Neurol. 2018 Feb;265(2):348-355. doi: 10.1007/s00415-017-8697-3. Epub 2017 Dec 14.

PMID:
29243005
9.

Common comorbidities and survival in MS: Risk for stroke, type 1 diabetes and infections.

Murtonen A, Kurki S, Hänninen K, Soilu-Hänninen M, Sumelahti ML.

Mult Scler Relat Disord. 2018 Jan;19:109-114. doi: 10.1016/j.msard.2017.10.019. Epub 2017 Nov 13.

PMID:
29190573
10.

Epidemiology of Guillain-Barré syndrome in Finland 2004-2014.

Sipilä JOT, Soilu-Hänninen M, Ruuskanen JO, Rautava P, Kytö V.

J Peripher Nerv Syst. 2017 Dec;22(4):440-445. doi: 10.1111/jns.12239. Epub 2017 Nov 15.

11.

25-Hydroxyvitamin D deficiency and risk of MS among women in the Finnish Maternity Cohort.

Munger KL, Hongell K, Åivo J, Soilu-Hänninen M, Surcel HM, Ascherio A.

Neurology. 2017 Oct 10;89(15):1578-1583. doi: 10.1212/WNL.0000000000004489. Epub 2017 Sep 13.

12.

Risk of osteoporotic fractures in multiple sclerosis patients in southwest Finland.

Åivo J, Kurki S, Sumelahti ML, Hänninen K, Ruutiainen J, Soilu-Hänninen M.

Acta Neurol Scand. 2017 May;135(5):516-521. doi: 10.1111/ane.12623. Epub 2016 Jun 22.

PMID:
27334254
13.

Admission sodium level and prognosis in adult Guillain-Barré syndrome.

Sipilä JO, Kauko T, Soilu-Hänninen M.

Int J Neurosci. 2017 Apr;127(4):344-349. doi: 10.3109/00207454.2016.1163551. Epub 2016 Mar 31.

PMID:
26971365
14.

Vitamin D Status During Pregnancy and Risk of Multiple Sclerosis in Offspring of Women in the Finnish Maternity Cohort.

Munger KL, Åivo J, Hongell K, Soilu-Hänninen M, Surcel HM, Ascherio A.

JAMA Neurol. 2016 May 1;73(5):515-9. doi: 10.1001/jamaneurol.2015.4800.

15.

Comorbid epilepsy in Finnish patients with adult-onset Huntington's disease.

Sipilä JO, Soilu-Hänninen M, Majamaa K.

BMC Neurol. 2016 Feb 10;16:24. doi: 10.1186/s12883-016-0545-z.

16.

[Respiratory disturbance during sleep induced by vagus nerve stimulator].

Joutsa J, Suomela M, Jutila L, Erkinjuntti M, Soilu-Hänninen M, Müller M.

Duodecim. 2015;131(19):1811-5. Finnish.

PMID:
26638666
17.

[Magnetic resonance imaging of the brain in the monitoring of immune therapy of multiple sclerosis].

Elovaara I, Soilu-Hänninen M, Kuusisto H, Martola J, Tienari P, Färkkilä M, Remes AM.

Duodecim. 2015;131(17):1571-80. Review. Finnish.

PMID:
26548104
18.

Vitamin D3 administration to MS patients leads to increased serum levels of latency activated peptide (LAP) of TGF-beta.

Åivo J, Hänninen A, Ilonen J, Soilu-Hänninen M.

J Neuroimmunol. 2015 Mar 15;280:12-5. doi: 10.1016/j.jneuroim.2015.01.005. Epub 2015 Jan 21.

PMID:
25773149
19.

[Cerebral nocardiosis as surprising cause of a convulsive seizure].

Kontturi A, Sonninen P, Soilu-Hänninen M, Talve L, Rahi M, Oksi J, Hohenthal U.

Duodecim. 2014;130(15):1531-5. Finnish.

PMID:
25211823
20.

The incidence and triggers of adult-onset Guillain-Barré syndrome in southwestern Finland 2004-2013.

Sipilä JO, Soilu-Hänninen M.

Eur J Neurol. 2015 Feb;22(2):292-8. doi: 10.1111/ene.12565. Epub 2014 Sep 8.

PMID:
25196425
21.

[Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].

Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.

Duodecim. 2013;129(7):765-70. Finnish.

PMID:
23720945
22.

A Randomised, Double-Blind, Placebo-Controlled Trial with Vitamin D3 in MS: Subgroup Analysis of Patients with Baseline Disease Activity Despite Interferon Treatment.

Aivo J, Lindsröm BM, Soilu-Hänninen M.

Mult Scler Int. 2012;2012:802796. doi: 10.1155/2012/802796. Epub 2012 Aug 5.

23.

[Paroxysmal feeling of suffocation during sleep--a diagnostic challenge].

Virtanen I, Kankuri-Tammilehto M, Soilu-Hänninen M.

Duodecim. 2012;128(8):820-3. Finnish.

PMID:
22616373
24.

Parechovirus infection preceding Guillain-Barré syndrome.

Linden S, Vuorinen T, Österback R, Soilu-Hänninen M.

J Neurovirol. 2012 Oct;18(5):434-6. doi: 10.1007/s13365-012-0104-3. Epub 2012 May 12. No abstract available.

PMID:
22581426
25.

C-reactive protein and seizures in focal epilepsy: a video-electroencephalographic study.

Alapirtti T, Waris M, Fallah M, Soilu-Hänninen M, Mäkinen R, Kharazmi E, Peltola J.

Epilepsia. 2012 May;53(5):790-6. doi: 10.1111/j.1528-1167.2012.03449.x. Epub 2012 Mar 29.

26.

A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis.

Soilu-Hänninen M, Aivo J, Lindström BM, Elovaara I, Sumelahti ML, Färkkilä M, Tienari P, Atula S, Sarasoja T, Herrala L, Keskinarkaus I, Kruger J, Kallio T, Rocca MA, Filippi M.

J Neurol Neurosurg Psychiatry. 2012 May;83(5):565-71. doi: 10.1136/jnnp-2011-301876. Epub 2012 Feb 22.

PMID:
22362918
27.

Characterization of CD4+ T cells specific for glutamic acid decarboxylase (GAD65) and proinsulin in a patient with stiff-person syndrome but without type 1 diabetes.

Hänninen A, Soilu-Hänninen M, Hampe CS, Deptula A, Geubtner K, Ilonen J, Knip M, Reijonen H.

Diabetes Metab Res Rev. 2010 May;26(4):271-9. doi: 10.1002/dmrr.1083.

28.

Expression of LIF and LIF receptor beta in Alzheimer's and Parkinson's diseases.

Soilu-Hänninen M, Broberg E, Röyttä M, Mattila P, Rinne J, Hukkanen V.

Acta Neurol Scand. 2010 Jan;121(1):44-50. doi: 10.1111/j.1600-0404.2009.01179.x.

PMID:
20074285
29.

T2-weighted high-intensity signals in the basal ganglia as an interesting image finding in Unverricht-Lundborg disease.

Korja M, Ferlazzo E, Soilu-Hänninen M, Magaudda A, Marttila R, Genton P, Parkkola R.

Epilepsy Res. 2010 Jan;88(1):87-91. doi: 10.1016/j.eplepsyres.2009.09.018. Epub 2009 Nov 6.

PMID:
19896804
30.

Serum level of CNTF is elevated in patients with amyotrophic lateral sclerosis and correlates with site of disease onset.

Laaksovirta H, Soinila S, Hukkanen V, Röyttä M, Soilu-Hänninen M.

Eur J Neurol. 2008 Apr;15(4):355-9. doi: 10.1111/j.1468-1331.2008.02080.x.

PMID:
18353124
31.

A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis.

Soilu-Hänninen M, Laaksonen M, Laitinen I, Erälinna JP, Lilius EM, Mononen I.

J Neurol Neurosurg Psychiatry. 2008 Feb;79(2):152-7. Epub 2007 Jun 19.

PMID:
17578859
32.

Nykykäsitys multippeliskleroosin patogeneesista.

Elovaara I, Soilu-Hänninen M.

Duodecim. 2006;122(18):2239-47. Finnish. No abstract available.

PMID:
17115645
33.

Downregulation of VLA-4 on T cells as a marker of long term treatment response to interferon beta-1a in MS.

Soilu-Hänninen M, Laaksonen M, Hänninen A, Erälinna JP, Panelius M.

J Neuroimmunol. 2005 Oct;167(1-2):175-82.

PMID:
16087245
34.

High sensitivity measurement of CRP and disease progression in multiple sclerosis.

Soilu-Hänninen M, Koskinen JO, Laaksonen M, Hänninen A, Lilius EM, Waris M.

Neurology. 2005 Jul 12;65(1):153-5.

PMID:
16009907
35.

Hyaluronate receptor (CD44) and integrin alpha4 (CD49d) are up-regulated on T cells during MS relapses.

Soilu-Hänninen M, Laaksonen M, Hänninen A.

J Neuroimmunol. 2005 Sep;166(1-2):189-92.

PMID:
15990174
36.

25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis.

Soilu-Hänninen M, Airas L, Mononen I, Heikkilä A, Viljanen M, Hänninen A.

Mult Scler. 2005 Jun;11(3):266-71.

PMID:
15957505
37.

LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival.

Butzkueven H, Zhang JG, Soilu-Hanninen M, Hochrein H, Chionh F, Shipham KA, Emery B, Turnley AM, Petratos S, Ernst M, Bartlett PF, Kilpatrick TJ.

Nat Med. 2002 Jun;8(6):613-9.

PMID:
12042813
38.

Induction of postnatal schwann cell death by the low-affinity neurotrophin receptor in vitro and after axotomy.

Syroid DE, Maycox PJ, Soilu-Hänninen M, Petratos S, Bucci T, Burrola P, Murray S, Cheema S, Lee KF, Lemke G, Kilpatrick TJ.

J Neurosci. 2000 Aug 1;20(15):5741-7.

39.

Treatment of experimental autoimmune encephalomyelitis with antisense oligonucleotides against the low affinity neurotrophin receptor.

Soilu-Hänninen M, Epa R, Shipham K, Butzkueven H, Bucci T, Barrett G, Bartlett PF, Kilpatrick TJ.

J Neurosci Res. 2000 Mar 15;59(6):712-21.

PMID:
10700008
40.

New treatments for multiple sclerosis.

Kilpatrick TJ, Soilu-Hänninen M.

Aust N Z J Med. 1999 Dec;29(6):801-10. Review. No abstract available.

PMID:
10677125
41.

Molecular mechanisms regulating motor neuron development and degeneration.

Kilpatrick TJ, Soilu-Hänninen M.

Mol Neurobiol. 1999 Jun;19(3):205-28. Review.

PMID:
10495104
42.

Nerve growth factor signaling through p75 induces apoptosis in Schwann cells via a Bcl-2-independent pathway.

Soilu-Hänninen M, Ekert P, Bucci T, Syroid D, Bartlett PF, Kilpatrick TJ.

J Neurosci. 1999 Jun 15;19(12):4828-38.

43.
44.
45.

Measles virus hemagglutinin mediates monocyte aggregation and increased adherence to measles-infected endothelial cells.

Soilu-Hänninen M, Hänninen A, Ilonen J, Salmi A, Salonen R.

Med Microbiol Immunol. 1996 Sep;185(2):73-80.

PMID:
8884738
46.
47.
48.

Facilitation of experimental allergic encephalomyelitis by irradiation and virus infection: role of inflammatory cells.

Erälinna JP, Soilu-Hänninen M, Röyttä M, Ilonen J, Mäkelä A, Salonen R.

J Neuroimmunol. 1994 Nov;55(1):81-90.

PMID:
7962484
49.

Semliki Forest virus infects mouse brain endothelial cells and causes blood-brain barrier damage.

Soilu-Hänninen M, Erälinna JP, Hukkanen V, Röyttä M, Salmi AA, Salonen R.

J Virol. 1994 Oct;68(10):6291-8.

50.

Urinary tract fistulas following abdominal hysterectomy.

Kiilholma PJ, Haarala M, Soilu-Hänninen M, Virtanen H, Mäkinen JI, Hirvonen T, Nurmi M.

Ann Chir Gynaecol Suppl. 1994;208:40-2.

PMID:
8092769

Supplemental Content

Loading ...
Support Center